Why is 4506.T rising pre-market today?

4506.T rose pre-market after recent quarterly beats on revenue and EPS and buying interest rotated into healthcare names on the JPX. Volume was below average, indicating targeted flows tied to earnings and news.

What are the key valuation metrics for Sumitomo Pharma?

Key metrics: P/E 5.95, P/S 2.07, P/B 3.47, EV/EBITDA 7.88 and market cap JPY 920,917,404,064.00. These suggest value relative to Japanese healthcare peers but require pipeline-risk adjustment.

What is Meyka AI's short-term forecast for 4506.T?

Meyka AI's forecast model projects a monthly level of JPY 2350.08 versus the current JPY 2318.00, an implied upside of 1.38%. Forecasts are model-based projections and not guarantees.

What risks should investors monitor for 4506.T?

Watch R&D setbacks, regulatory delays, and international launch timing. Also monitor cash conversion cycle and potential margin pressure given inventory days of 176.84 and a debt-to-equity ratio near 0.99.

JP Stocks

4506.T Sumitomo Pharma +1.00% pre-market 03 Jan 2026: JPX signals upside

ByHuzaifa Zahoor January 3, 2026January 3, 2026

4506.T stock opened pre-market up 1.00% to JPY 2318.00 on 03 Jan 2026 after thin-volume strength on the JPX. The move follows a run of positive quarterly reports and above-consensus revenue and EPS prints in 2025, sending buying interest into biopharma and specialty drug names in Japan. We review the price action, fundamentals, technicals and a model-based forecast to frame near-term upside for Sumitomo Pharma Co., Ltd.